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Summary
The igM monoclonal autoantibodies of patients with
demyelinating paraproteinaemic polyneuropathy recognize a
carbohydrate structure present on both myelin-associated
glycoprotein (MAG) and protein zero (Po). These auto-
antibodies are sufficient to cause the disease but the mechan-
ism of demyelination remains unclear. We have analysed
nerve biopsies from eight patients with polyneuropathy and
anti-MAG antibodies by quantitative immunohistochemistry
and find a concordant pattern of reduced expression ofmyelin
markers with the loss of myelinated fibres. We report here
novel features of this disease, in particular a selective lack
of detectable MAG in a large proportion of myelinated fibres
containing PQ, myelin basic protein (MBP) and periaxin.
There is also an inverse correlation of the distribution of
MAG in peripheral nerve myelin with the serum anti-MAG
antibody titres but no correlation of these titres with the loss
of myelinated fibres. Double immunofluorescence staining of
paraproteinaemic polyneuropathy (PPN) nerves shows anti-
MAG IgM deposited on the periphery of myelinated fibres
associated with or lacking MAG staining. These data suggest
that the binding of anti-MAG antibodies to MAG and/or
other myelin component(s) results in MAG downregulation
and may have an essential role in the molecular mechanisms
leading to demyelination and partial regeneration in this
disease.
Keywords: myelin-associated glycoprotein; anti-MAG autoantibodies; paraproteinaemic polyneuropathy; enzyme
immunohistochemistry; quantitative image analysis
Abbreviations: anti-MAG PPN = PPN cases with anti-MAG autoantibody activity; GalC = galactocerebroside; GFAP =
glial fibrillary acidic protein; HNK-1, human natural killer cells-1 mAb; mAb = monoclonal antibody; MAG = myelin-
associated glycoprotein; MBP = myelin basic protein; M-IgM = monoclonal immunoglobulin IgM; Po = myelin protein zero;
PPN = paraproteinaemic polyneuropathy
Introduction
In a large proportion of patients with demyelinating peripheral
PPN, monoclonal IgM antibodies (M-IgM) react primarily
with the human natural killer cells-1 (HNK-1) carbohydrate
determinant of MAG (Braun et al., 1982; McGarry el al.,
1983; Schuller-Petrovic et al., 1983; Steck et al., 1983; Frail
et al., 1984), in addition to myelin glycolipids (Ilyas et al.,
1984) and Po (Bollensen et al., 1988). Here we consider
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exclusively these cases associated with anti-MAG auto-
antibodies (anti-MAG PPN). The anti-MAG PPN is a slowly
progressive disease with distally pronounced loss of sensory
and motor functions (Kaku et al., 1994). The main
pathological features are demyelinating lesions and deposits
of autoantibodies associated with a 23 nm spacing between
the separated leaflets of the intermediate line that results in
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a widening of the outer myelin lamellae (King and Thomas,
1984). These lesions are not associated with inflammatory
cellular infiltrates or any signs of acute cytotoxicity. The
mechanism of presumable alteration of the blood-nerve
barrier is not known. There are compelling arguments for a
causative role of the patient's anti-MAG M-IgM: (i) the
injection of patient's anti-MAG M-IgM in chicks results in
demyelination with characteristic widening of the myelin
lamellae (Tatum, 1993); (ii) this ultrastructural alteration is
the site where anti-MAG M-IgM deposits of the correspond-
ing class of light chain have been localized (Mendell et al,
1985; Monaco et al., 1990; Lach et al., 1993); (iii) intraneural
injection of anti-MAG M-IgM in species expressing HNK-
1-type carbohydrates causes focal demyelination (Trojaborg
et al., 1989). Nerve biopsies usually contain demyelinating
lesions with active zones of remyelination, and sometimes
axonal damage of variable severity (Vital et al., 1989).
In order to get further insights into the pathogenesis of the
anti-MAG M-IgM neuropathy we have looked for coordinate
changes of various myelin components by quantitative
immunohistochemistry and have analysed the expression and
distribution of several myelin and non-myelin markers in
biopsies of patients with anti-MAG M-IgM neuropathy. While
we found a concordant pattern of reduced expression of
myelin markers with the loss of myelinated fibres, the
observation of a disproportional reduction of fibres with
detectable MAG levels together with the finding of highly
significant inverse correlation with the serum anti-MAG titres
suggests that MAG is the major target of the M-IgM
autoantibodies.
resolved by sodium dodecylsulphate-polyacrylamide gel
electrophoresis and blotted to nitrocellulose membranes as
described by Burger et al. (1990). Serial dilutions of patient's
antibodies binding to MAG were assayed by Western blot
analysis using 1:1000 anti-human IgM (Fc)-peroxidase
(Nordic, Tilburg, Netherland) in blocking buffer (1.5 mg ml"'
casein, 0.2% Tween 20 in phosphate buffered saline) and
Fast-DAB as substrate (Sigma). The antibody titre is given as
the reciprocal of the highest serum dilution at which antibody
binding to the 100 kDa protein band is detected.
Polyclonal and monoclonal antibodies
Myelin-associated glycoprotein and periaxin were selected
as markers of early myelination, while Po, MBP and
galactocerebroside (GalC) antigens are myelin-specific
markers appearing at later stages of myelination. The
following antibodies to myelin specific proteins were used:
D3A2G5 (Burger et al., 1990) or 513 (Boehringer; Poltorak
et al., 1987) anti-MAG monoclonal antibodies (mAbs), P07
(Archelos et al, 1993) or D4IE4 (Miller et al, 1984) anti-
Po mAbs, HNK-1 mAb (ATCC TIB 200; Abo and Balch,
1981), 130-137 anti-MBP mAb (Boehringer), anti-periaxin
polyclonal (Gillespie et al, 1994), and mGalC/D12 anti-
GalC mAb (Boehringer). The antibodies against non-myelin
proteins were: G-A-5 mAb (Boehringer; Debus et al, 1983)
or Z-334 (Dako) polyclonal anti-glial fibrillary acidic protein
(GFAP), 15E2E2 mAb (Boehringer) or Z-311 (Dako)
polyclonal anti-protein S-100, and NN18 anti-neurofilament
160 kDa mAb (Boehringer; Weber et al, 1983).
Material and methods
Tissue specimens
Peroneal nerve biopsies from eight patients with para-
proteinaemic polyneuropathy and monoclonal anti-MAG IgM
antibodies (Bo 1, -4, -6, -7, -9, -10, -11,-12) and three
autopsy controls (two sural nerves and one peroneal nerve)
without neurological disease were embedded in O.C.T.
compound (Miles, Elkhart, Ind., USA) and snap frozen. The
inclusion criteria for this study were anti-MAG antibody
titres greater than 100 by Western blot analysis of CNS
myelin and the absence of structural artifacts or high
background staining in the nerve biopsies. All these patients
were evaluated at the Department of Neurology, University
Hospital of Bordeaux. They underwent routine EMG and
nerve conduction studies. The peroneal nerve biopsies were
studied by light and electron microscopy, while IgM deposits
were demonstrated by direct immunofluorescence microscopy
(Vital etal, 1989).
Anti-MAG M-IgM titres
Myelin was isolated from human brain and human peripheral
nerve (cauda equina) by sucrose gradient centrifugation,
Immunohistochemistry
Cryostat sections (7 |im thick) were mounted on gelatin-
chromalum-coated slides and fixed with 10% v/v buffered
formalin for 20 min. It was necessary to extend the fixation
to 5 h and to add a mild lipid extraction step with 15%
ethanol for 40 h to reliably detect molecules which are
associated with the myelin membrane (MAG, Po, MBP,
HNK-1 and GalC). Cytoplasmic or non-myelinating Schwann
cell markers did not require this step. Blocking of endogenous
peroxidase activity was achieved in 80% methanol:19.4%
water:0.6% H2C>2 for 20 min at room temperature. Saturation
of nonspecific binding sites was performed with a blocking
buffer (1% v/v normal goat serum, 2% w/v fish skin gelatin,
0.25% v/v Triton X-100 in phosphate buffered saline) for 15
min at room temperature (Bergoffen et al, 1993). The
blocking and incubation procedures for MBP detection were
performed without Triton X-100 to avoid detergent extraction
of MBP. Prior to incubation, all antibodies including
peroxidase coupled secondary antibodies were diluted with
blocking buffer except the anti-MBP antibody which was
diluted in phosphate buffered saline. The peroxidase substrate
3-amino-9-ethylcarbazole (0.027% w/v; H2O2 0.03% v/v) in
0.1 M sodium acetate buffer pH 5.2 was incubated with
samples for 20 min at room temperature in the dark. Every
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antibody incubation was performed on two slides, of which
one was weakly counterstained by haemalum (1 min, Mayer's
Haemalum; Merck). The sections were mounted with Kaiser's
glycerin-gelatin (Merck) and a cover glass. All the antibodies
selected for this study gave a staining pattern on normal
tissues consistent with the known antigen distribution. The
antibodies were tested for the absence of cross-reactivities
with other antigens and the conditions of lowest background
were selected.
Histological staining
For histological staining of the myelin, cryostat sections
(7 \x.m thick) were fixed for 1 h in 10% buffered formalin.
Slides were washed in double-distilled water and were
stained for 1 h in a 0.2% solution of Solochrom-Cyanin
(Eriochromcyanin R, Fluka 45560). The sections were washed
for 10 min in running tap water and then differentiated in a
10% solution of ammonium iron (III) sulphate for 10-20 s,
until the nuclei had lost their colour. A further wash for 10
min in running tap water and twice in double-distilled water
followed. Tissues were counterstained with eosin (0.5% w/v
in 24% ethanol) for 1 min. For cell nuclear count, some
sections were stained with 0.1% (w/v) toluidine blue O
(Merck) in 0.1% Na2B4O7 solution for 1 min. Sections
were finally dehydrated in ethanol, cleared with xylene and
mounted with Entellan®neu (Merck) and a cover glass.
Image analysis
A maximum of 50 test fields (84X84 (j.m each) were analysed
from each nerve section using a Zeiss Axiophot microscope
and a X63 oil objective. A maximum of 20 test fields was
randomly assigned for a single nerve fascicle. Test fields
which contained artifacts or which partially crossed the
outside boundaries of a nerve fascicle were excluded. This
sampling strategy allowed to analyse ~40% of the total cross-
sectional surface of the nerve fascicules from control autopsy
tissues and 60-90% of the corresponding value from patient
biopsies. A colour image of each test field was captured by
a colour CCD camera and the camera signal was decoded
with a S-RGB colour decoder into three red-green-blue
(RGB) signal channels. The triple signal was digitized and
stored on a personal computer (VIDAS 2.1, Kontron
Electronic, Carl Zeiss AG, Zurich, Switzerland). Constant
values for gain (117) and offset (255) were set to ensure
comparable signal intensities. Red-green-blue-decoded
colour images were further transferred and compressed on
digital audio tapes for later use. The colour images of each
test field were discriminated with constant red-green-blue
intensity to obtain a binary image of either the zones stained
red by the immunohistochemistry, or the regions stained
blue by the Solochrome-Cyanin staining. The percentage of
antibody- or physical dye-stained surface was defined and
estimated as the ratio of the discriminated area divided by
the entire test field area and was stored as a single value for
each test field. Files of 50 such values per patient and
per antibody were stored and converted for mathematical,
graphical and statistical operations with various analysis
softwares. The number of Solochrome, Po and MAG-positive
fibres was counted up to 50 digitalized test fields. The ratio
of MAG-positive fibres to the total number of myelinated
fibres (positive by Po or periaxin) was then calculated.
Statistics
The intervariability of the different staining results averaged
30% (range 10-50%) between the three control autopsy
specimens. A representative autopsy control with minimal
background and high reproducible staining was selected. The
mean percentage surface value of six different incubations
with each of the 13 antibodies on the reference autopsy
control tissue was taken as the general mean control value
and was comparable with the mean percentage surface value
obtained with the three controls. The intravariability between
these six determinations was lower than 10%, except for
anti-GalC antibody determinations which showed greater
variations. The stained surface of each patient relative to this
general mean control is expressed as a percentage normalized
to the nerve fascicular area. These percentage values were
averaged between all the patients and expressed as relative
levels of PNS markers (percentage mean±SE). The bivariate
regression plot and the statistical Fischer RtoZ test were used
for correlation analysis (StatView software v4.02, Abacus
Concepts, Berkeley, Calif., USA).
Double immunostaining
Single and double immunostaining of the nerve biopsies
from patients with anti-MAG neuropathy and from a reference
autopsy control case were performed on serial sections as
described in the immunohistochemistry section above and
will be described in detail elsewhere. Briefly, incubation was
performed first with D3A2G5 anti-MAG (or D4IE4 anti-P0
on a separate section) followed by fluorochrome indo-
carbocyanin 3-conjugated goat anti-mouse IgG (H + L)
secondary antibodies. Incubation with antihuman IgM
constituted the third step. IgM deposits were demonstrated
with (i-chain specific goat antihuman IgM conjugated to
the indodicarbocyanin 5 fluorochrome. A Leitz confocal
microscope was used for double-channel laser scanning
imaging (optical scan z = 0.25 nm). Indocarbocyanin 3 label
was recorded as a red false colour, while indodicarbocyanin
5 label was false-colourized green.
Results
Neuropathy features and myelin stain
The clinical, electrophysiological and histological data are
consistent with a predominantly demyelinating non-
inflammatory neuropathy in all cases (Table 1). The serum
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Table 1 IgM reactivity and neuropathy features in patients with anti-MAG antibodies
Patient
Bo 1
Bo 4
Bo 6
Bo 7
Bo 9
Bo 10
Bo 11
Bo 12
Sex
M
M
M
F
F
M
M
M
Anti-MAG* titre
1000
40000
100
50000
30000
10000
60000
6000
Clinical data
Symptoms1^
LL
UL + LL
LL
LL
UL + LL
LL
LL+tremor
LL
Neuropathy
feature*
SMNP
SMNP
SNP
SNP
SMNP
SNP
SNP
SNP
Nerve studies
Peroneal
MNCV§
25
26
Not available
27
12
20
27
19
IgM deposits^1 WML*
+
Kappa +
Not done
Not done +
Kappa +
Kappa +
Kappa + + +
Kappa +
*Average of triplicate determinations by Western blot. ^Symptoms at neurological examination: UL = upper limbs; LL = lower limbs.
*SNP = sensory neuropathy; SMNP = sensorimotor neuropathy. ^Peroneal MNCV = peroneal motor nerve conduction velocity (m s~').
^Direct immunofiuorescence study of IgM deposits in myelin sheaths: kappa = positive for kappa light chain; — = negative. *WML =
widening of myelin lamellae at ultrastructural examination: + = presence; - = absence.
of all the patients contained anti-MAG IgM antibodies and
the anti-MAG titres were highly reproducible both in triplicate
determinations by Western blot or single determination by
enzyme-linked immunosorbent assay. A sensory neuropathy
of the lower limbs predominates in five patients, while
three patients have a sensory-motor neuropathy. The nerve
conduction velocity ranges from 12 to 27 ms~' and the mean
of 22.3 ms" 1 is similar to the value of 22.9 m s"1 reported
elsewhere (Nobile-Orazio et al., 1994). Solochrom is a
physical myelin stain which binds a complex of ferric ions
to the highly negatively charged myelin sheaths and both
large and small myelinated fibres are strongly stained blue
(Page, 1970) (Fig. 1 A). A marked decrease in the number of
myelinated fibres is evident in some biopsies of anti-MAG
PPN (Fig. IB). However, for all the biopsies the loss of
Solochrom stained fibres does not correlate with the anti-
MAG M-IgM titres.
Staining pattern of myelin markers
On control nerves, both the D3A2G5 (Fig. 1C) and the 513
anti-MAG polypeptide mAbs (results not shown) give a
similar staining of concentric rings corresponding presumably
to the periaxonal collar (arrows, Fig. 1C), paranodal loops
and Schmidt-Lanterman incisures (arrowheads, Fig. 1C). By
contrast with PPN nerves, both anti-MAG mouse mAbs
occasionally and intensely stain the entire thickness of some
of the myelin sheaths (arrows, Fig. ID). The most striking
feature of anti-MAG PPN biopsies is the lack of detectable
MAG in numerous myelinated fibres. Examination of serial
sections confirmed that these MAG negative fibres had a
normal pattern of Po and MBP expression. Both the anti-
MBP mAb (Fig. II) and the D4IE4 (Fig. IE) or the P07 anti-
Po polypeptide mAbs stain the compact myelin of control
nerves; in addition, some axonal staining is seen with the
P07 mAb (results not shown). The anti-MBP (Fig. U) and
anti-P0 mAbs (Fig. IF) stain fewer myelinated fibres in PPN.
In addition to the known periaxonal localization (Gillespie
et al., 1994), anti-periaxin antibodies stain the entire thickness
of myelinated fibres and the cytoplasm of myelinating
Schwann cells in control (Fig. 1G) and PPN nerves (Fig. 1H).
In two cases with anti-MAG PPN (Bo 4 and Bo 9) the anti-
periaxin antibodies stain a large number of characteristically
very small fibres (arrows, Fig. 1H). This subset of periaxin-
positive fibres are not stained by mAbs to Po (Fig. IF) or
MBP (Fig. U), while we have not been able to establish
whether this characteristic subset of very small periaxin-
positive fibres are MAG positive or negative. In the PNS the
HNK-1 mAb is known to stain glycolipids and numerous
glycoproteins including MAG and Po. On control nerves,
HNK-1 strongly stains both large and small myelinated
fibres, while it uniformly and weakly stains non-myelinating
Schwann cells (Fig. IK). By contrast, HNK-1 labels non-
myelinating Schwann cells of PPN nerves frequently and
intensely in areas close to nuclei and axons (arrows, Fig. 1L).
Moreover, small Schwann cells sometimes appear as paired
striped structures, a pattern typical of clusters of regeneration
(Vital and Vallat, 1987) (arrowheads, Fig. 1L).
In each of the eight anti-MAG PPN biopsies the population
of myelinated fibres is similarly stained by two different anti-
Po mAbs. Using the D3A2G5 anti-MAG mAb, however, on
average only half of the P0-positive myelinated fibres contain
detectable MAG (Table 2), in a range of 17-83%. By contrast
in the reference control nerves 85% of the Po myelinated
fibres are MAG positive (Table 2). The proportion of MAG-
positive fibres to those stained with antibodies to periaxin,
another myelin marker, is also reduced in all the anti-MAG
PPN specimens (Table 2). While in the reference control
nerves there is a similar number of periaxin and Po-positive
fibres, in six anti-MAG PPN patients there are somewhat
fewer periaxin-positive than P0-positive fibres (Table 2),
this proportion amounting to 8 7 ± 3 % (range 81-89%).
Interestingly, the two patients with a prominent staining of
very small fibres, Bo 4 and Bo 9 have a greater number of
fibres stained with periaxin than with Po (Table 2) with 275%
and 105% of the number of P0-positive fibres, respectively.
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Table 2 Number and proportion of antibody-stained fibres per square millimetre
Specimen
Bo 1
Bo 4
Bo 6
Bo 7
Bo 9
Bo 10
Bo 11
Bo 12
Mean±SE§
Control
Po*
(X103)
6.6
1.0
3.0
5.0
3.4
2.9
8.9
7.2
4.7±0.9
6.6
MAG/P0
(%)
83.1
54.1
49.7
45.6
49.7
43.3
17.4
42.6
48.0±6.4
85.4
MAGt
(X103)
5.5
0.6
1.4
2.3
1.7
1.2
1.5
3.0
2.2±0.5
5.6
MAG/pax*
(%)
93.3
19.7
57.3
46.0
47.3
53.1
20.2
51.2
48.5+8.1
85.0
Periaxin*
(X103)
5.9
2.8
2.5
5.0
3.6
2.3
7.6
6.0
4.5±0.7
6.6
Pax*/P0
(%)
89.0
275.2
86.6
99.2
105.0
81.4
86.2
83.1
113.2±23.3
100.5
*D4IE4 anti-Po mAb; tD3A2G5 anti-MAG mAb; *anti-periaxin antiserum (pax = periaxin); mean and standard error of the eight PPN
nerve biopsies above.
In Patient Bo 4, 80% of the total number of periaxin-positive
fibres do not stain for MAG.
Staining pattern of non-myelin markers
Several sural (Fig. 1M), peroneal and femoral control nerves
from autopsy are entirely negative with the anti-GFAP mAb
(up to a 1:8 dilution), while seven out of the eight anti-MAG
PPN nerve biopsy specimens strongly express GFAP in a
small subset of non-myelin forming Schwann cells (Fig. IN).
By contrast, a polyclonal antiserum raised against GFAP
stains a large subset of Schwann cells in control nerves and
considerably more Schwann cells in PPN (see quantitative
data, below). There is, however, a discrepancy between our
results and published data which make use of the polyclonal
anti-GFAP antibodies. This antibody has been reported to be
negative on human frozen nerve tissue section (Mancardi
et ai, 1991; Bianchini et al., 1992). In our hands, human
nerves obtained from autopsy were positive with this
antiserum. Differences in fixation or immunohistochemistry
protocols may provide the most likely explanation for this
discrepancy. Qualitative analysis of the cellular nuclei stained
by toluidine blue indicated an increased cellularity in PPN
nerves compared with control nerves. Whether this increased
cellularity is accounted for by new myelinating periaxin-
positive Schwann cells, non-myelinating GFAP-positive
Schwann cells or by fibroblastic proliferation cannot be
determined.
Protein S-100, another Schwann cell specific marker, is
exclusively localized in the cytoplasm of mature myelinating
and non-myelinating Schwann cells of control nerves (arrows,
Fig. 1O). The compact myelin is not labelled, while the
uncompact myelin regions of Schmidt-Lanterman inci-
sures (arrowheads. Fig. 10), paranodal loops and the
periaxonal collar are labelled on transverse or longitudinal
sections (data not shown). In anti-MAG PPN, the overall S-
100 staining pattern is similar to control, however, non-
myelinating Schwann cells are more prominent (Fig. IP).
Antibodies to neurofilament 160 kDa, a member of the
neuron-specific type IV intermediate filaments, stain
exclusively the axoplasm of both myelinated and
unmyelinated fibres in control and anti-MAG PPN (results
not shown). A minority of myelinated fibres do not stain
with this mAb in some anti-MAG PPN biopsy specimens
(results not shown).
Quantitative immunohistochemistry
Loss of myelin
A total of 12000 (6800 for anti-MAG PPN and 5200
for control) immunohistochemistry colour images of nerve
cryostat sections from anti-MAG PPN and control specimens
were processed using the VIDAS image analysis system. The
proportion of the nerve fascicular area stained by anti-myelin
antibodies is shown in Table 3. The average myelin area
which remains in the eight anti-MAG PPN cases is 38% of the
reference control myelin surface as estimated by Solochrom
staining (Fig. 2). Similar values are obtained using the
antibodies to GalC (45%). Quantitative results with anti-GalC
antibodies were difficult to interpret because considerable
variations were recorded on different occasions {see Material
and methods). The anti-P0 (57% and 56%), anti-MBP (54%)
and anti-periaxin staining (54%) give a higher estimate of
the myelin area which remains in PPN than the results
obtained with Solochrom staining (Fig. 2). However, the
Solochrom and immunohistochemical staining procedures are
not strictly comparable.
Interestingly, although the loss of myelin is prominent in
most of the anti-MAG PPN biopsies, the fascicular areas
stained by antibodies to the Schwann cell marker protein
S100 (96% and 104%) and the axonal neurofilament 160
(102%) are similar in anti-MAG PPN and control
specimens (Fig. 2).
Decreased MAG staining level
The average MAG area relative to control (MAG level)
which remains in all the anti-MAG PPN cases is smaller
than the average area stained with Po, MBP and periaxin
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Fig. 1 Photomicrograph of a control sura] nerve (A, C, E, G, I, K. M and CX) or a peroneal nerve biopsy from Patient Bo 9 (B. D. F. H.
J, N and P) or Patient Bo 7 (L). Solochrom myelin physical stain and eosin counterstain (A and B) or immunohistochemical staining
with D3A2G5 anti-MAG mAb (C. D), D4IE4 anti-PO mAb (E and F), anti-periaxin antiserum (G and H), anti-MBP mAb (I and J).
HNK-1 mAb (K and L), anti-GFAP mAb (M and N), and ami protein S-100 mAb (O and P). Haemalum counterstain (I. J. M, N. O
and P). In C, arrows point to periaxonal staining while arrowhead points to Schmidt-Lanterman incisures. In D. arrows point to myelin
fibres
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which shows an intense and thick band of MAG staining. In H, arrows point to very small fibres which are characteristically periaxin-
positive PQ negative. In L, arrows point to areas surrounding nuclei or axons, while arrowheads point to paired stripes structures typical
of cluster of regeneration. In O, arrows point to cytoplasm of Schwann cells while arrowhead points to Schmidt-Lanterman incisures.
The bar represents 25 nm and the same magnification was used for each photomicrograph.
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Table 3 Percentage of the nerve fascicular surface stained by anti-myelin antibodies*
Specimen
Bo 1
Bo 4
Bo 6
Bo 7
Bo 9
Bo 10
Bo 11
Bo 12
Mean±SE t f
Control**
MBPt
43.7
3.3
11.1
27.6
14.6
10.4
22.9
30.6
20.5±4.7
37.8
MAG*
7.2
0.2
1.9
1.5
0.6
0.9
1.3
2.3
2.0±0.8
4.2
MAG§
2.3
0.1
1.5
1.5
0.5
0.5
0.6
1.1
1.0+0.3
4.0
31.5
2.0
12.6
22.8
6.7
7.5
25.0
26.0
16.7±3.9
30.0
Po#
34.6
2.2
16.8
27.6
7.4
8.4
28.6
31.1
19.6±4.4
34.5
Periaxin**
47.2
6.0
14.9
23.3
11.2
9.9
41.3
28.4
22.8±5.4
42.0
*Nerve sections from PPN and control were stained with anti-myelin antibodies. Between 40 and 50 test fields of 84X84 (im were
analysed from each nerve section using the VIDAS image analysis. The percentage of the surface which is stained by antibodies in each
nerve fascicule was estimated as the ratio of the discriminated area divided by the entire test field area. These percentage values were
then averaged between all the nerve fascicules and expressed as the average percentage of the stained nerve fascicular surface. * 130-137
anti-MBP mAb. *D3A2G5 anti-MAG mAb. §513 anti-MAG mAb. 'D4IE4 anti-Po mAb. *P07 anti-Po mAb. **Anti-periaxin antiserum.
**Mean and SE of the eight PPN nerve biopsies above. **Mean of the reference control nerve determined from six different incubations.
oo
s
in
Fig. 2 Relative levels of PNS markers in eight PPN biopsies. The levels correspond to the fractions of
nerve fascicular area as determined in Table 2 and are expressed as percent of control. Filled bars
represent the difference of these percentage levels between PPN and control tissue, (p) = polyclonal
antiserum; (m) = mAb.
antibodies (Fig. 2). The average MAG area normalized to
control which is identified with the anti-MAG D3A2G5 mAb
(47%) is larger than with the anti-MAG 513 mAb (25%;
Fig. 2). This difference is caused by the biopsy specimen of
Patient Bo 1, which actually shows a larger stained nerve
fascicle area amounting to 169% of control with the D3A2G5
anti-MAG mAb, while theremaining MAG level amounts to
58% of control with the 513 anti-MAG mAb. An independent
staining of the Bo 1 specimen and control resulted in more
comparable values of 98% and 83% of remaining MAG levels
with the D3A2G5 and 513 anti-MAG mAbs, respectively.
Another cause is the higher background, weaker and more
diffuse staining obtained with the 513 anti-MAG mAb than
with the D3A2G5 mAb on control and PPN nerves (data
not shown).
Increased GFAP and HNK-1 staining level
The surface staining, with either the polyclonal or monoclonal
anti-GFAP antibodies (essentially of non-myelinating
Schwann cells), was considerably larger in anti-MAG PPN
biopsies than in control tissue and corresponded to 154%,
881% respectively of control (Fig. 2). The apparently large
difference between the two antibodies is caused by the control
nerves which are positive with the polyclonal but negative
with the monoclonal anti-GFAP antibody. Consequently the
ratio of the GFAP level in PPN relative to control nerve is
larger with the monoclonal Ab than with the polyclonal
(Fig. 2).
The relative areas stained with the HNK-1 mAb, i.e.
both non-myelin and myelin forming Schwann cells, were
increased in anti-MAG PPN and amounted to 113% of
control (Fig. 2).
Correlation between anti-MAG antibody titre
and MAG or Po
An index of MAG distribution in myelinated fibres can be
defined as the ratio of the surface stained by the D3A2G5
or 513 anti-MAG mAbs to the area stained by the respective
Po, MBP or periaxin antibodies. In the anti-MAG PPN
patients, this relative MAG distribution in myelin shows a
significant inverse correlation with the anti-MAG M-IgM
antibody titres. A significant correlation factor of r= -0.752
and a probability of P = 0.029 is obtained with the D3A2G5
anti-MAG mAb and the D4IE4 anti-PO mAb surface ratio
(Fig. 3). Using the 513 anti-MAG mAb instead of the
D3A2G5 mAb results in a similar correlation with anti-
MAG M-IgM antibody titres (r = -0.74, P = 0.033). Highly
significant correlations are found between the anti-MAG
titres and the MAG distribution relative to either MBP
[D3A2G5 mAb: r = -0.95, P < 0.0001 (Fig. 3); 513 mAb:
r =-0.83, P = 0.007] or periaxin (D3A2G5 mAb: r = -0.88,
P = 0.002; 513 mAb: r = -0.75, P = 0.0029).
To evaluate the relative density of MAG fibres in myelin
we calculated the ratio of fibres stained by the D3A2G5 anti-
MAG mAb and the number of myelinated fibres stained by
either the D4IE4 or the P07 anti-P0 mAb or stained by the
anti-periaxin antiserum. There is no significant correlation
between the anti-MAG antibody titres and the density of
MAG fibres relative to either Po (r = -0.472, P = 0.252) or
periaxin (r = -0.661, P = 0.0753). When Patient Bo 4 with
a high content of periaxin-positive fibres is excluded from
the analysis (Table 2), no significant correlation emerges
between the serum anti-MAG titres and the density of MAG
fibres relative to either periaxin (r = -0.626, P = 0.1416) or
P 0 ( r =-0.536, P = 0.2310).
There is no correlation between the anti-MAG M-IgM
antibody titres and the relative distribution of Po in PPN
myelin (D4IE4 anti-P0 /MBP surface ratios: r = -0.41, P =
0.332; D4IE4 anti-Po/periaxin surface ratio: r = -0.32, P=
0.463). There is no correlation either between these titres
and the loss of myelin measured as the percentage of nerve
fascicular surface relative to control that is stained with
anti-P0, anti-MBP, anti-GalC or anti-periaxin antibodies (as
determined in Fig. 2), confirming the previously mentioned
negative correlation with the Solochrom stain. No correlation
was found between the results with anti-GFAP or HNK-1
mAbs and the anti-MAG M-IgM antibody titres.
Immunofluorescence staining
Double immunostaining for IgM autoantibodies and MAG in
PPN nerves revealed four different populations of myelinated
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Fig. 3 Correlation of MAG distribution in PPN myelin with
serum anti-MAG M-IgM titres. The relative MAG distribution in
the myelin of each PPN biopsy was determined as the ratio of the
nerve fascicular area stained with the D3A2G5 anti-MAG mAb
relative to either the D4IE4 anti-P0 mAbs (A) or the 130-137
anti-MBP mAbs (B).
fibres (Fig. 4). The first population contains strongly stained
MAG fibres without IgM deposits. The second and third
populations include IgM positive myelin fibres with strong
or weak MAG labelling, respectively. In this population of
fibres, the IgM paraprotein was deposited as a thin ring at
the periphery of myelinated fibres. The fourth population
consist of IgM-positive fibres without MAG staining in which
IgM are deposited either as thick rings at the periphery or in
the entire thickness of myelin sheaths.
Discussion
The anti-MAG M-IgM neuropathy is characterized by a
distally pronounced progressive chronic demyelination
(Mendell et al., 1985). The circulating anti-MAG M-IgM
autoantibodies make deposits that characteristically outline
the outer aspect of some of the remaining myelin sheaths
and alter their ultrastructure (King and Thomas, 1984;
Mendell et al., 1985). Our biopsy material obtained from
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Fig. 4 Photomicrograph of a peroneal nerve biopsy from Patient
Bo 12. Double-immunofluorescence staining with D3A2G5 anti-
MAG mAb (red label) and human IgM deposits (green label).
Four large myelinated fibres are stained by anti-MAG and anti-
IgM antibodies without colour overlapping (stars). Note the
weaker MAG staining in two of these fibres. Massive IgM
deposits are present in three additional myelinated fibres lacking a
MAG staining (large arrows). Small arrows point to periaxonal
staining while arrowheads point to Schmidt-Lanterman incisures.
The bar represents 2.5 urn.
eight patients with anti-MAG M-IgM neuropathy shows
variable loss of myelinated fibres, a finding comparable with
previous reports (Mendell et al., 1985; Vital et al., 1989).
The reduction of myelinated fibres seen in these biopsies
with the Solochrom myelin stain correlates with the decrease
of fibres labelled with antibodies to Po, MBP and periaxin
and, to a lesser degree, MAG. There is also a good agreement
between the density of Po+ or MBP+ fibres and the density
of myelinated fibres determined by electron microscopy of
ultrathin sections from separate tissue blocks (data not
shown).
An intriguing result of our study of anti-MAG PPN nerves
is the lack of detectable MAG staining in a large population
of remaining myelinated fibres. Accordingly there is a larger
decrease of MAG-positive staining fascicular area than
observed with other myelin markers by quantitative
immunohistochemistry. The inability to detect MAG in a
large population of myelinated fibres is not attributable to a
masking effect by M-IgM bound to MAG carbohydrate
epitopes because MAG is detectable with two different mouse
mAbs which recognize each a distinct MAG polypeptide
epitope. Moreover, two-colour immunofluorescence confocal
microscopy studies of PPN nerves show the presence of
MAG and IgM deposits in some myelin fibres while MAG
negative myelinated fibres are associated with extensive IgM
deposits. In the former population of myelinated fibres,
MAG staining appears as concentric rings corresponding
presumably to the periaxonal collar (inner ring) and Schmidt-
Lanterman incisure (outer ring) while IgM autoantibodies
are deposited at the periphery of the myelinated fibres without
overlapping the MAG staining. Interestingly, MAG staining
intensities ranging from weak to strong (comparable with
control nerves or with myelinated fibre devoid of IgM in
PPN nerves) were associated with a thin ring of IgM deposits.
This decreased MAG staining could be the result of reduced
MAG expression. By contrast, myelinated fibres devoid of
MAG staining were often associated with thick IgM deposits
either at the periphery or in the entire thickness of the
myelin sheaths.
The normal staining pattern observed with the myelin
markers Po, MBP and periaxin in myelin sheaths devoid of
detectable MAG represents an unexpected finding. Many of
these MAG" PQ+ myelinated fibres could be functionally
normal in PPN: (i) the ratio of MAG-positive to P0-positive
fibres does not correlate with the loss of myelinated fibres;
(ii) nerve conduction velocities were normal (Montag et al.,
1994) and no loss of myelinated fibres occurred in young
mice with disrupted MAG genes (Li et al., 1994; Montag
et al., 1994); (iii) the axons enwrapped by the MAG" Po+
fibres seem unaffected as the nerve fascicular surface stained
by antibodies to neurofilament 160 remains unchanged
between the PPN and control nerves. This selective loss of
MAG in myelinated fibres could result either from an
antibody-mediated antigenic modulation or from a down-
regulation of gene expression and may represent a chronic
state in the anti-MAG PPN. As a long-term effect of MAG
loss both axon and myelin degeneration can, however, occur,
resulting in a very slowly progressive neuropathy. Our results
are compatible with the notion that MAG plays a major role
in the maintenance of myelin integrity rather than in its
formation. This has been shown recently to be the case in
old mice with disrupted MAG genes (Fruttiger et al., 1995),
where both axonal and myelin degeneration is taking place.
Another important observation of this study is that the
circulating anti-MAG autoantibody titres show an inverse
correlation with the relative distribution of MAG in the
remaining myelin sheaths. By contrast, the proportion of
MAG to P0-positive myelinated fibres does not correlate
with the patients' serum anti-MAG autoantibody titres. The
functional consequence of the relationship between the serum
anti-MAG antibody titres and the distribution of MAG
in myelin suggests that the binding of anti-MAG M-IgM
autoantibodies to MAG could result in an altered pattern of
MAG expression. The autoantibodies in PPN might also
affect the size of the remaining MAG+ fibres and, at present,
it cannot be excluded that they exert at least some of their
effects by binding to other myelin components in addition
to MAG. Both the selective loss of MAG and the qualitative
changes of MAG staining in the remaining myelin argue for
a disregulation of MAG expression in PPN. In contrast to
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MAG, the Po distribution in the remaining PPN myelin
sheaths does not seem to be affected directly by the presence
of the anti-MAG M-IgM autoantibodies, although both MAG
and Po carry the same HNK-1 carbohydrate epitopes. This is
consistent with reports showing a higher apparent avidity
of anti-MAG M-IgM antibodies for the multiple HNK-1
carbohydrate epitopes of MAG than for the unique Po epitope
(Burger et al, 1990; Brouet et al., 1992; Ogino et al., 1994).
The localization of the four myelin markers MAG, Po,
MBP and GalC in human control peripheral nerves is
consistent with previous reports (Trapp, 1990; Mezei, 1993;
Poduslo, 1993; Martini, 1994). In particular, the concentric
rings of MAG staining seen in cross-sections of control
nerves is in agreement with the localization of MAG in
uncompact myelin, mainly in Schmidt-Lanterman incisures,
paranodal loops and in the penaxonal region where it is
believed to be involved in the tight apposition of the
axolemma and the inner lip of the myelinating Schwann cell
(Trapp and Quarles, 1982; Trapp et al., 1984). In contrast to
this pattern, the localization of MAG in PPN nerves
occasionally differs from the typical concentric rings of
control nerves. In occasional biopsies, an intense and thick
band of MAG staining is observed to varying degrees in
some of the myelinated fibres. One interpretation of this
observation is that there could be an accumulation of fibres
with multiple layers of non-compacted MAG+ Schwann cell
membranes (Trapp and Quarles, 1984). Theoretically the
binding of the anti-MAG M-IgM could perturb adhesion
properties of MAG to a presumptive receptor and thereby
produce ultrastructural changes. Alternatively, the
autoantibodies could perturb signalling functions involving
molecules associated with MAG, such as the Fyn protein
tyrosine kinase. Indeed, disruption of the Fyn kinase gene in
mice leads to hypomyelination (Umemori et al., 1994).
It has been suggested that periaxin could associate with
the cytoplasmic domain of MAG at the penaxonal collar of
myelinating Schwann cell where it might be important for
the regulation of axon-Schwann cell interactions (Gillespie
et al., 1994). Using the same anti-periaxin antiserum we find
staining throughout the entire thickness of myelin in the
nerves of both newborn rats (data not shown) and adult human
controls. These observations indicate that the expression of
MAG is not coordinately linked with that of periaxin in PPN
nerves: on average, 50% of periaxin-positive fibres lacked
MAG in six out of eight anti-MAG PPN cases, and in the
remaining two anti-MAG PPN cases there was an increased
population of very small fibres with periaxin but not Po or
MBP staining. The latter may represent either new
myelinating fibres or remyelinating fibres since PQ and MBP
are markers of late myelination, while periaxin may be one
of the first myelin protein expressed in myelinating Schwann
cells (P. Brophy, personal communication). The fact that
more nuclei are found in PPN nerves and more surface is
stained by anti-GFAP mAbs is consistent with a proliferation
of non-myelin forming Schwann cells. Conceivably, periaxin
might be the first marker expressed in new or regenerating
myelin, followed by MAG and later on by Po and MBP. The
presence of periaxin+Po~ fibres is consistent with an increased
potential for remyelination or new myelin formation in
this disease.
The apparent loss of myelinated fibres in anti-MAG PPN
nerves occurs concomitantly with a prominent increase of
the GFAP marker of non-myelin forming Schwann cells
(Mokuno et al., 1989; Mancardi et al., 1991; Bianchini et al.,
1992; Feinstein et al., 1992). This increase is specific to PPN
since it was absent in other neuropathies such as Charcot-
Marie-Tooth type 1A, hereditary neuropathy with liability
to pressure palsies, Guillain-Barre syndrome or chronic
inflammatory demyelinating polyradiculoneuropathy (J.-M.
Gabriel, B. Erne and A. J. Steck, unpublished results). The
increased number of nuclei as well as the presence of
Schwann cell hypertrophy in some of the PPN nerves biopsies
are consistent with varying degrees of gliosis. In addition to
GFAP, we also observed an increased expression of the HNK-
1 marker in anti-MAG PPN nerves. Among the many
molecules containing the HNK-1 epitope, MAG and Po are
not involved (this study), while neuron cell adhesion molecule
could be a possible candidate for the HNK-1 up-regulation
in the MAG negative fibres since neuron cell adhesion
molecule was found to be up-regulated in MAG knock-out
mice (Montag et al., 1994). We have some preliminary
evidence that neuron cell adhesion molecule is indeed up-
regulated in PPN nerves (J.-M. Gabriel, B. Erne and A. J.
Steck, unpublished results).
Conclusion
The results from this study provide novel evidence that MAG
may be an important functional target of the anti-MAG M-
IgM autoantibodies in PPN. In addition, original features of
this disease have been identified by phenotypic marker
analysis which could not be detected with morphological
histopathological techniques. Future investigations should
attempt to delineate the populations of demyelinating and
remyelinating fibres in anti-MAG M-IgM paraproteinaemic
polyneuropathy as a prerequisite step to understanding the
mechanisms of demyelination in PPN.
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